Maggie L. Shaw

This new meta-analysis from World Health Organization and University of Cape Town investigators analyzed adverse posthospitalization discharge outcomes and related risk factors among persons living with HIV.

The FDA based its approval on OlympiA trial data, which show the PARP inhibitor has the ability to reduce risks of invasive breast cancer recurrence, second cancers, and death, and to improve overall survival.

This new investigation from the United Kingdom evaluated health care professionals’ (HCP) perceptions and implementation of practices that focus on open-source automated insulin delivery (OS-AID).

This new study investigated cardiovascular disease (CVD) risk outcomes among patients with a serious mental illness (SMI) attending primary care clinics that were part of HealthPartners and Park Nicollet in Minnesota and Wisconsin.

This new study of pediatric patients with type 1 diabetes from France and Belgium investigated the effectiveness of insulin delivery via closed-loop and open-loop systems.

This new study evaluated the influence of transmission bottlenecks on HIV-1 infection virulence by comparing outcomes between penile-vaginal intercourse and anal intercourse, and found more severe disease among heterosexual individuals compared with men who have sex with men.

This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as their concerns over follow-up

A new study of patients receiving care for acute heart failure at Rambam Health Care Campus in Haifa, Israel, investigated how their clinical outcomes might be affected by elevated lactate levels and primary acid-base disorders.

A new report from the CDC details how services for HIV, sexual health, and viral hepatitis were affected in the aftermath of the COVID-19 pandemic, according to data from 2019 and 2020.

This new analysis of commercial and Medicare Advantage claims from all 50 states investigated utilization of and testing trends for coronary artery disease (CAD) among adults aged 18 and older presenting with new-onset heart failure.

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.

A new study has investigated the influence of xanthine oxidase activity and mitochondrial DNA damage–associated molecular patterns on heart failure and cardiac remodeling among Black adults with resistant hypertension.

This new study of women who underwent mammographic screening for breast cancer at a Breast Cancer Surveillance Consortium facility between 2000 and 2018 investigated potential implications of overdiagnosis.

An abstract presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) bore out the results of an Italian investigation into a potential link between persons living with HIV (PLWH) taking newer antiretroviral therapies and neurocognitive disorder prevalence.

A new study from Japan has investigated possible associations between cognitive frailty and overall prognosis among elderly individuals who have heart failure.

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).

This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.

This new study investigated the relationship between cardiac function and hemodynamics among individuals presenting with heart failure with preserved ejection fraction (HFpEF) and normal levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP).

This new subanalysis of data from the Rotterdam Study investigated life expectancy among women and men who live a healthy lifestyle and do or do not have heart failure.

A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.

This study investigated the relationships seen among premenopausal women with a family history of breast cancer and their breast tissue density as seen at their annual mammographic screening.

This new investigation, a subanalysis of participant data from the Atherosclerosis Risk in Communities study, examined race- and gender-based differences of heart failure (HF) risk at an older age.

This new study explores the utility and potential of noninvasive liquid biopsies as a method of early detection in lung cancer.

A new study from North Carolina has investigated individuals’ experiences with and perspectives on their receipt of HIV-related care while incarcerated in 1 of 21 jails in the state.

This new study from investigators at University of Calgary investigated the potential of midwall striae fibrosis to predict hospital admission for heart failure.

This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.

This new analysis of more than 11 million veterans investigated risks of several cardiovascular diseases beyond the first 30 days after COVID-19 infection.

A new report from the Republic of Korea compared outcomes among women following neoadjuvant chemotherapy and mastectomy who did or did not receive radiotherapy.

Circulating tumor DNA (ctDNA) as a detection method for renal cell carcinoma (RCC) was investigated in a new review that summarizes evidence on ctDNA use and potential.